Table 5.
Effects of sesamin on obesity.
| Reference | Experimental Model | Dosage | Administration Mode | Administration Duration | Experimental N | Response |
|---|---|---|---|---|---|---|
| Cell and Cell Lines | ||||||
| Freise et al. (2013) | 3 T3-L1 preadipocytes | 5, 10, 20, 40 µM episesamin | N/A | 24 h | 12 | - Reduction in the accumulation of lipid droplets - Inhibition of GLUT-4 and vascular endothelial growth factor expression in preadipocytes - Reduction in intracellular lipid droplets and induced apoptosis in mature adipocytes |
| Badmaev et al. (2015) | Pancreatic lipase assay | 0.1, 1, 10, 100 µg/mL | N/A | 15 min | 2 | Inhibition of pancreatic triacylglycerol lipase (PTL) activity by S. indicum extract |
| Tai et al. (2019) | Human hepatocellular carcinoma cell line (HepG2) Human intestinal cell line (LS174T) Hepatoma cell line (HepaRG) |
20, 40 μM 20, 40 μM 5, 10 μM |
N/A N/A N/A |
24 h 24 h 2 weeks |
4 3 3 |
-Sesamin reduced valproate-and rifampin-induced hepatic lipogenesis - Sesamin selectively induces reverse cholesterol transport- (RCT-) related genes in LS174Tcell -Sesamin inhibits the mRNA and protein expression of T0901317-induced LXRα downstream gene |
| Animal Models | ||||||
| Ide et al. (2001) | Sprague-Dawley rats | 0.1 w/w% (1 g/kg), 0.2 w/w% (2 g/kg), 0.4 w/w% (4 g/kg) |
Oral | 15 days | 7–8 | Suppression of hepatic FAS expression |
| Chinnala et al. (2014) | Sprague-Dawley rats | 200, 400 mg/kg | Oral | 40 days | 6 | Decrease in body weight and food intake |